Ofev (Nintedanib Esylate) Patent Expiration, LOE Window & CMS Spending

Ofev (Nintedanib Esylate) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2026-04-01 (last listed 2029-12-07), 9 AB generics, $2.20B 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN205832 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2026-04-01
Last Listed Patent or Exclusivity Date2029-12-07
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$2.20B
2024 Medicare Part D Spend$2.09B
2024 Medicaid Spend$114.1M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 19.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.